Nutriband Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Nutriband şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-15.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-15.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Recent updates

Nutriband opens a new branch in Ecuador with plans to expand into the South American market

Jul 22

Nutriband: Advancing Transdermal Delivery Of Injectable Drugs

Nov 01

Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?

Oct 06

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NTRB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NTRB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Nutriband Piyasaya Karşı Temettü Getirisi

NTRB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NTRB)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (NTRB) (3 yıla kadar)	n/a

Önemli Temettü: NTRB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NTRB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NTRB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NTRB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Nutriband Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Nutriband Inc. (NasdaqCM:NTRB) announces an Equity Buyback for $1 million worth of its shares.

Recent updates

Nutriband Inc.'s Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica

Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology

Nutriband Inc. (NasdaqCM:NTRB) announces an Equity Buyback for $1 million worth of its shares.

Second quarter 2025 earnings released: US$0.15 loss per share (vs US$0.11 loss in 2Q 2024)

Nutriband Inc. Provides Product Development Update for its Lead Product Aversa Fentanyl

Nutriband Inc. Appoints Sergei Glinka to Its Board of Directors

Nutriband Inc. announced delayed annual 10-K filing

Full year 2024 earnings released: US$0.69 loss per share (vs US$0.53 loss in FY 2023)

Nutriband Inc. announced that it expects to receive $8.4 million in funding

Is Nutriband (NASDAQ:NTRB) A Risky Investment?

Nutriband Inc. Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch

Nutriband Inc. Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented At 2024 American Academy of Pain Medicine Annual Meeting

Nutriband Inc. Announces Data on the Incidence of Transdermal Patch Abuse and Accidental Pediatric Exposure Will Be Presented At the 2024 American Academy of Pain Medicine Annual Meeting

New minor risk - Shareholder dilution

Nutriband Inc., Annual General Meeting, Jan 21, 2024

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2023)

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?

Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 2Q 2023)

Nutriband Inc. Launches AI Tape Brand Direct- to Consumer Offerings

New major risk - Share price stability

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.075 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nutriband Inc. to Officially Launch AI Tape brand in First Quarter 2023

Consensus forecasts updated

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to US$13.29

Nutriband Inc., Annual General Meeting, Dec 09, 2022

Consensus EPS estimates fall by 23%

Second quarter 2023 earnings: Revenues miss analyst expectations

Nutriband GAAP EPS of -$0.12, revenue of $0.5M

Nutriband opens a new branch in Ecuador with plans to expand into the South American market

Nutriband Inc.(NasdaqCM:NTRB) dropped from Russell Microcap Value Index

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$14.00

Nutriband Inc. Announces Board Appointments

Consensus revenue estimates fall by 40%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nutriband: Advancing Transdermal Delivery Of Injectable Drugs

Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?

Price target decreased to US$24.00

Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Med Tech Ltd for its Closed System Transfer Device

Nutriband Inc. (OTCPK:NTRB) completed the acquisition of Transdermal and Health product manufacturing business of Pocono Coated Products LLC for $7.5 million.

Nutriband Inc. (OTCPK:NTRB) agreed to acquire Transdermal and Health product manufacturing business of Pocono Coated Products LLC.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin